目的 通过测定纳米活性碳吸附的表阿霉素经脱吸附后，脱吸附出来的表阿霉素的结构是否发生改变，来推测纳米活性碳吸附表阿霉素的稳定性，进而为临床使用纳米活性碳吸附表阿霉素行局部淋巴化疗寻找实验依据。方法 通过物理脱吸附方法使表阿霉素-纳米活性碳混悬液中纳米活性碳吸附的表阿霉素释放出来，再通过超高效液相色谱质谱联用法（LC-MS法）测定脱吸附后的表阿霉素结构是否发生改变。结果 表阿霉素-纳米活性碳混悬液经过脱吸附后提取的表阿霉素行LC-MS法检测提示：脱吸附后提取的表阿霉素样品液与表阿霉素标准液的LC-MS图基本一致。结论 被纳米活性碳吸附的表阿霉素，经脱吸附后其结构并未发生改变。
Objective To determine the best matching concentration of carbon nanoparticles suspension injection adsorb epirubicin by measuring the combination ratio of carbon nanoparticles suspension injection combined with epirubicin under different matching conditions. And then, to prove the adsorbability of carbon nanoparticles suspension injection adsorb epirubicin in vitro. Methods Firstly, epirubicin-carbon suspension of different concentrations will be prepared. The second, high performance liquid chromatography mass spectrometry（LC-MS） was used to assay the concentration of free epirubicin, and calculate the content of epirubicin that was combinated with carbon nanoparticles suspension injection. The difference of the ratio of carbon nanoparticles suspension injection combined with epirubicin under different matching conditions will be compared in the end. Results The combination ratio of carbon nanoparticles suspension injection combined with epirubicin solution of 5, 10, and 15 mg/ml were 85.6%, 85.7%, and 31.8%, respectively. Conclusions The adsorbability of carbon nanoparticles suspension injection adsorb epirubicin is favourable in vitro. Best matching concentration of carbon nanoparticles suspension injection adsorb epirubicin may be epirubicin solution of 5-10 mg/ml.